{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:23:10Z","timestamp":1773080590314,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of the study was to assess the correlation of commonly used laboratory tests with clinical activity, degree of kidney involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study included 28 patients with active AAV (BVAS\u2009\u2265\u20093). The following tests were performed: MPO-ANCA, PR3-ANCA, peripheral blood count, ESR, CRP, procalcitonin, creatinine, GFR, urea, albumin, fibrinogen, d-dimer, components of the C3 and C4 complement systems, urinalysis with sediment evaluation and diurnal proteinuria. The assessments were conducted twice: at study entry (A0) and after 6 months (A6) (BVAS\u2009=\u20090).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At the time of inclusion in the study, the mean creatinine concentration was 3.39\u00a0mg\/dl (GFR 33.17 ml\/min\/1.73\u00a0m\u00b2), after achieving remission in 11 patients (39.3\u2009%) GFR remained below 30 ml\/min\/1.73\u00a0m\u00b2, 4 patients (14.3\u2009%) continued renal replacement therapy, and 3 patients (10.7\u2009%) with advanced renal failure died. Microscopic hematuria occurred in 80.9\u2009% of the studied population, withdrew in most patients, strongly correlated with renal involvement <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and was not related to disease severity <jats:italic>p<\/jats:italic>\u2009=\u20090.147. CRP, ESR, fibrinogen, d-dimer, albumin and hemoglobin in the peripheral blood showed a strong correlation with the clinical activity of AAV and well identified severe patients. High procalcitonin concentrations correlated with a severe form of the disease, pulmonary involvement with respiratory failure and alveolar hemorrhage (mean 3.41 ng\/ml, median 0.91 ng\/ml, SD 7.62, <jats:italic>p<\/jats:italic>\u2009=\u20090.000), and were associated with the occurrence of infectious complications and the need to administer antibiotic therapy. ANCA antibodies were useful in the evaluation of patients with AAV, the amount of antibodies did not correlate with the severity of vasculitis (<jats:italic>p<\/jats:italic>\u2009=\u20090.685) and the results in many patients did not match the expected assumptions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CRP, ESR, fibrinogen, d-dimers, albumin and hemoglobin in the peripheral blood correlate well with the activity of vasculitis and identify severe patients. The resolution of microscopic hematuria suggests remission of the disease in the renal area. Procalcitonin may be slightly increased in patients with active AAV without infection, high concentrations are strongly associated with infectious complications. ANCA antibodies should always be interpreted in the context of the observed clinical symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02495-8","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T04:03:05Z","timestamp":1629950585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-2072","authenticated-orcid":false,"given":"Magdalena","family":"Mosakowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota Brodowska","family":"Kania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Szamotulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Rymarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142aw","family":"Niemczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"issue":"8","key":"2495_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.1780330807","volume":"33","author":"RY Leavitt","year":"1990","unstructured":"Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al: The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis. Arthritis Rheum. 1990 33(8):1101\u20137.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2495_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum."},{"key":"2495_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al: EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75: 1583\u20131594.","journal-title":"Ann Rheum Dis"},{"key":"2495_CR4","first-page":"479","volume":"81","author":"E Wiatr","year":"2013","unstructured":"Wiatr E, Gawryluk D: Pierwotne systemowe zapalenia naczy\u0144 zwi\u0105zane z przeciwcia\u0142ami przeciw-cytoplazmatycznymi (ANCA) \u2014 rekomendacje diagnostyczne i lecznicze: Pneumo\u00acnol. Alergol. Pol. 2013; 81: 479\u2013491.","journal-title":"Pol"},{"key":"2495_CR5","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/ndt\/17.12.2077","volume":"17","author":"CA Stegeman","year":"2002","unstructured":"Stegeman CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant (2002) 17: 2077\u20132080.","journal-title":"Nephrol Dial Transplant"},{"key":"2495_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","volume":"50","author":"R Suppiah","year":"2011","unstructured":"Suppiah R, Mukhtyar C, Flossmann O, Alberici F, Baslund B, Batra R et al: A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology 2011;50:899\u2013905.","journal-title":"Rheumatology"},{"issue":"1","key":"2495_CR7","first-page":"21","volume":"75","author":"E Houben","year":"2017","unstructured":"Houben E, van der Heijden JW, van Dam B, Bax WA, Voskuyl AE, Penne EL: Screening for renal involvement in ANCA-associated vasculitis: room for improvement? Neth J Med. 2017 75(1):21\u201326.","journal-title":"Neth J Med"},{"issue":"2","key":"2495_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10067-015-3162-0","volume":"35","author":"H Hanaoka","year":"2016","unstructured":"Hanaoka H, Ota Y, Takeuchi T, Kuwana M: Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis. Clin Rheumatol. 2016 ;35(2):495\u2013500.","journal-title":"Clin Rheumatol."},{"issue":"7","key":"2495_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3899\/jrheum.111608","volume":"39","author":"D Geetha","year":"2012","unstructured":"Geetha D, Seo P, Ellis C, Kuperman M, Levine SM: Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy. J Rheumatol. 2012 ;39(7):1413\u20137.","journal-title":"J Rheumatol."},{"issue":"1","key":"2495_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12882-017-0763-7","volume":"18","author":"L Lv","year":"2017","unstructured":"Lv L, Chang DY, Li ZY, Chen M, Hu Z, Zhao MH: Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis? BMC Nephrol. 2017;18(1):354.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2495_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.rdc.2010.05.006","volume":"36","author":"R Cartin-Ceba","year":"2010","unstructured":"Cartin-Ceba R, Peikert T, Specks U: Pathogenesis of ANCA-Associated Vasculitis. Rheum Dis Clin North Am. 2010; 36(3): 463\u2013477.","journal-title":"Rheum Dis Clin North Am"},{"key":"2495_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","volume":"72","author":"PA Monach","year":"2013","unstructured":"Monach PA, Warner RL, Tomasson G, Specks U, Stone JH, Ding L et al: Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis 2013;72:1342\u20131350.","journal-title":"Ann Rheum Dis"},{"key":"2495_CR13","first-page":"341","volume":"21","author":"CR Hind","year":"1984","unstructured":"Hind CR, Winearls CG, Lockwood CM, Rees AJ, Pepys MB: Objective monitoring of activity in Wegener\u2019s granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol 1984;21:341\u20135.","journal-title":"Clin Nephrol"},{"issue":"1","key":"2495_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.berh.2018.07.005","volume":"32","author":"E Csernok","year":"2018","unstructured":"Csernok E, Bossuyt X: Investigations in systemic vasculitis. The role of the laboratory. Best Pract Res Clin Rheumatol. 2018 ;32(1):52\u201362.","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"11","key":"2495_CR15","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3899\/jrheum.100302","volume":"37","author":"AI K\u00e4lsch","year":"2010","unstructured":"K\u00e4lsch AI, Csernok E, M\u00fcnch D, Birck R, Yard BA, Gross W et al: Use of highly sensitive C-reactive protein for followup of Wegener\u2019s granulomatosis. J Rheumatol. 2010 ;37(11):2319\u201325.","journal-title":"J Rheumatol."},{"issue":"1","key":"2495_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12882-018-0933-2","volume":"19","author":"L Yang","year":"2018","unstructured":"Yang L, Xie H, Liu Z, Chen Y, Wang J, Zhang H et al: Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018;19(1):138.","journal-title":"BMC Nephrol"},{"issue":"7","key":"2495_CR17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-A","volume":"40","author":"OK Eberhard","year":"1997","unstructured":"Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R: Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus\/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250\u20136.","journal-title":"Arthritis Rheum."},{"issue":"8","key":"2495_CR18","first-page":"1531","volume":"25","author":"F Moosig","year":"1998","unstructured":"Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL: Elevated procalcitonin levels in active Wegener\u2019s granulomatosis. J Rheumatol. 1998 ;25(8):1531\u20133.","journal-title":"J Rheumatol."},{"issue":"1","key":"2495_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/BOR.0b013e32835ad3ca","volume":"25","author":"J Springer","year":"2013","unstructured":"Springer J, Villa-Forte A: Thrombosis in vasculitis. Curr Opin Rheumatol. 2013 ;25(1):19\u201325.","journal-title":"Curr Opin Rheumatol."},{"issue":"4","key":"2495_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2008.099051","volume":"68","author":"Y Allenbach","year":"2009","unstructured":"Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L: French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener\u2019s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 ;68(4):564\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"2495_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3109\/03009742.2015.1006247","volume":"44","author":"P Willeke","year":"2015","unstructured":"Willeke P, K\u00fcmpers P, Schl\u00fcter B, Limani A, Becker H, Schotte H: Platelet counts as a biomarker in ANCA-associated vasculitis. Scand J Rheumatol. 2015;44(4):302\u20138.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"2495_CR22","doi-asserted-by":"publisher","first-page":"e97843","DOI":"10.1371\/journal.pone.0097843","volume":"9","author":"TT Ma","year":"2014","unstructured":"Ma TT, Huang YM, Wang C, Zhao MH, Chen M. Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis. PLoS One. 2014;9(5)e97843.","journal-title":"PLoS One."},{"issue":"6","key":"2495_CR23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1055\/s-0038-1650390","volume":"75","author":"O Hergesell","year":"1996","unstructured":"Hergesell O, Andrassy K, Nawroth P: Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost. 1996 ;75(6):892\u20138.","journal-title":"Thromb Haemost."},{"issue":"3","key":"2495_CR24","doi-asserted-by":"publisher","first-page":"R140","DOI":"10.1186\/ar3873","volume":"14","author":"J Yuan","year":"2012","unstructured":"Yuan J, Gou SJ, Huang J, Hao J, Chen M, Zhao MH. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2012;14(3):R140.","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"2495_CR25","doi-asserted-by":"publisher","first-page":"J276-86","DOI":"10.1016\/j.jaut.2009.11.014","volume":"34","author":"M Chen","year":"2010","unstructured":"Chen M, Daha MR, Kallenberg CG: The complement system in systemic autoimmune disease. J Autoimmun. 2010 ;34(3):J276-86.","journal-title":"J Autoimmun"},{"issue":"7","key":"2495_CR26","doi-asserted-by":"publisher","first-page":"e0158871","DOI":"10.1371\/journal.pone.0158871","volume":"11","author":"JF Augusto","year":"2016","unstructured":"Augusto JF, Langs V, Demiselle J, Lavigne C, Brilland B, Duveau A, et al. Low Serum Complement C3 Levels at Diagnosis of Renal ANCA-Associated Vasculitis Is Associated with Poor Prognosis. PLoS One. 2016;11(7)e0158871.","journal-title":"PLoS One."},{"key":"2495_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1523-1755.1998.00807.x","volume":"53","author":"EC Hagen","year":"1998","unstructured":"Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G et al: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. ECuBCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743\u2013753.","journal-title":"Kidney Int"},{"key":"2495_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/rheumatology\/40.2.147","volume":"40","author":"T Girard","year":"2001","unstructured":"Girard T, Mahr A, Noel L-H, Cordier J-F, Lesavvre P, Andre M-H, Guillevin L: Are antineutrophil cytoplasmic antibodies a marker of relapse in Wegener\u2019s granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40: 147\u2013151.","journal-title":"Rheumatology (Oxford)"},{"key":"2495_CR29","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","volume":"43","author":"MM Boomsma","year":"2000","unstructured":"Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG et al: Prediction of relapses in Wegener\u2019s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025\u201333","journal-title":"Arthritis Rheum"},{"key":"2495_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","volume":"147","author":"JD Finkielman","year":"2007","unstructured":"Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW et al; WGET Research Group: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611\u201319.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2495_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0025-6196(12)65300-2","volume":"64","author":"U Specks","year":"1989","unstructured":"Specks U, Wheatley CL, McDonald TJ, Rohrbach MS, DeRemee RA. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener\u2019s granulomatosis. Mayo Clin Proc. 1989;64(1):28\u201336.","journal-title":"Mayo Clin Proc."},{"issue":"11","key":"2495_CR32","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1001\/archinte.1989.00390110055012","volume":"149","author":"JW Tervaert","year":"1989","unstructured":"Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF et al: Association between active Wegener\u2019s granulomatosis and anticytoplasmic antibodies. Arch Intern Med. 1989 ;149(11):2461\u20135.","journal-title":"Arch Intern Med"},{"issue":"10","key":"2495_CR33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/ard.2008.094714","volume":"68","author":"B Terrier","year":"2009","unstructured":"Terrier B, Saadoun D, S\u00e8ne D, Ghillani P, Amoura Z, Deray G et al: Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis. 2009 ;68(10):1564\u201371.","journal-title":"Ann Rheum Dis."},{"key":"2495_CR34","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2215\/CJN.02500317","volume":"12","author":"JC Jennette","year":"2017","unstructured":"Jennette JC, Nachman PH: ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol 12: 1680\u20131691, 2017.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02495-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02495-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02495-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T04:03:35Z","timestamp":1629950615000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02495-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02495-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"7 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Bioethics Committee of the Military Institute of Medicine in Warsaw on June 18, 2014 (No. 26\/WIM\/2014). We obtained written informed consent from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA\/Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest related to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"290"}}